PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 10, 2026Neurology3 citations

Role of Tocilizumab in Severe CNS Inflammatory Presentations in Children

View Full Paper
AMAmaar MarefiEGE GrassoLMLoren McLendon

Key Points

  • The aim is to evaluate the effectiveness of tocilizumab in treating severe CNS inflammatory presentations in children.
  • Class IV evidence study design
  • Assessment of clinical outcomes
  • Population involved children with acute-severe CNS inflammation
  • Tocilizumab improved clinical outcomes for children with severe CNS inflammation.
  • The findings suggest a positive therapeutic effect of tocilizumab on acute severe events.

Abstract

This study provides Class IV evidence that TCZ improves clinical outcomes in children with acute-severe CNS inflammatory events.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Marefi et al. (2026) studied this question.

synapsesocial.com/papers/69d894526c1944d70ce0547bhttps://doi.org/10.1212/wnl.0000000000214926
Ask AI
Helpful
Bookmark
Share
View Full Paper